Oncobiologics (OTLK) to Release Earnings on Wednesday

Key Points

• Oncobiologics is expected to announce its Q3 2025 earnings on August 13th, with analysts predicting an EPS of ($0.42) and revenue of $1.66 million.
• In its last earnings report on May 15th, Oncobiologics reported an EPS of ($0.40), beating expectations by $0.15.
• A Goldman Sachs Group Inc. increased its stake in Oncobiologics by 74.1%, reflecting growing institutional interest in the company.

Oncobiologics (NASDAQ:OTLK - Get Free Report) will likely be issuing its Q3 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.42) per share and revenue of $1.66 million for the quarter.

Oncobiologics (NASDAQ:OTLK - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.15. On average, analysts expect Oncobiologics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Oncobiologics Price Performance

Shares of NASDAQ OTLK traded up $0.06 during mid-day trading on Friday, hitting $1.90. The company had a trading volume of 540,897 shares, compared to its average volume of 914,678. The stock has a market cap of $63.78 million, a price-to-earnings ratio of -2.09 and a beta of 0.26. Oncobiologics has a 12 month low of $0.87 and a 12 month high of $8.32. The firm's 50 day simple moving average is $1.90 and its two-hundred day simple moving average is $1.68.

Institutional Trading of Oncobiologics

An institutional investor recently raised its position in Oncobiologics stock. Goldman Sachs Group Inc. lifted its position in Oncobiologics, Inc. (NASDAQ:OTLK - Free Report) by 74.1% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 103,524 shares of the company's stock after buying an additional 44,063 shares during the period. Goldman Sachs Group Inc. owned approximately 0.32% of Oncobiologics worth $126,000 at the end of the most recent reporting period. Institutional investors own 11.20% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on OTLK shares. Ascendiant Capital Markets cut their price target on Oncobiologics from $24.00 to $21.00 and set a "buy" rating on the stock in a report on Friday, June 6th. Guggenheim reissued a "buy" rating on shares of Oncobiologics in a report on Tuesday, May 20th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Oncobiologics currently has an average rating of "Moderate Buy" and an average target price of $9.60.

Oncobiologics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.